BURLINGTON, Mass. & TAIPEI, Taiwan—Terason, a global ultrasound imaging company, has announced a partnership with AmCad BioMed Corporation that will provide Terason’s ultrasound imaging technology for AmCad’s innovative Obstructive Sleep Apnea (OSA) solution, AmCAD-UO.
The partnership, according to Terason, will address a strong market need for more efficient solutions that help physicians evaluate the risk of OSA, a disorder that affects over 425 million people worldwide.
“We are pleased that our ultrasound imaging technology is being combined with AmCad’s AI and advanced signal processing to change the way physicians assess and diagnose obstructive sleep apnea,” said Dr. Alice Chiang, Terason’s CEO and founder and industry pioneer. “Using the intuitive solution that leverages the superior clarity of Terason’s ultrasound images, physicians can access diagnostic information about their patient’s upper airway in less than an hour – turning a formerly inefficient process into a convenient outpatient procedure.”
AmCAD-UO, the world’s first FDA-cleared solution for upper airway assessment, uses artificial intelligence (AI) to analyze and reconstruct upper airway ultrasound images acquired from awake patients using Terason’s ultrasound imaging technology. This allows doctors to more quickly evaluate the root cause of sleep apnea and offer assessment for moderate/severe OSA patients.
The AmCAD-UO solution is reportedly receiving early acclaim in the industry. It has secured its first U.S. use at University Hospitals Cleveland Medical Center, a major not-for-profit medical complex in Cleveland, Ohio.
“We are very optimistic that the deployment of our AmCAD-UO solution at University Hospitals Cleveland Medical Center will pave the way to broad acceptance in an industry that is looking for a more efficient way to evaluate obstructive sleep apnea. Our unique technology and partnership with Terason open endless possibilities for clinical research, prediction of surgery success, treatment analysis and follow-ups,” stated Yi -Li Lee, president of AmCad BioMed.
This isn’t Terason’s only recent collaboration — back in August, Terason partnered with DiA Imaging Analysis Ltd., a provider of AI-based solutions for ultrasound analysis, to provide its cardiac solutions on Terason’s point-of-care ultrasound devices.
“Left ventricle analysis represents the most frequent indication for an echo study and is pivotal for patient evaluation, management, and as an indicator for treatment initiation. We always strive to offer users the most innovative solutions,” noted Dr. Alice Chiang, Terason’s CEO, founder and industry pioneer. “By joining with DiA, we will empower users with our best-in-class devices together with DiA’s most powerful automated algorithms, that provide superior solutions for managing patients with heart failure or cardiovascular disease.”
DiA’s FDA-cleared and CE-marked flagship cardiac solution, LVivo Toolbox, leverages its pattern recognition, machine learning and deep learning-based technology to identify cardiac functions and abnormalities. LVivo’s AI-based algorithms generate fast, quantitative and objective results that support clinicians’ decision-making process and reduce the subjectivity associated with cardiac ultrasound analysis.
“DiA and Terason have many shared values, and I am pleased that we have joined forces. The point-of-care ultrasound market is evolving quickly, and AI is driving this market. Partnering with Terason is another step toward accomplishing DiA’s vision to make ultrasound analysis smarter and accessible to all,” added said Hila Goldman-Aslan, DiA’s CEO and co-founder.